

DRUG ABSORPTION AND DISTRIBUTION PRACTICE TEST (SAMPLE)

STUDY GUIDE



SAMPLE STUDY GUIDE WITH LIMITED QUESTIONS

VISIT US ONLINE FOR
THE FULL VERSION STUDY GUIDE

<https://drugabsorptiondistrib.examzify.com>



Copyright © 2026 by Examzify - A Kaluba Technologies Inc. product.

ALL RIGHTS RESERVED.

No part of this book may be reproduced or transferred in any form or by any means, graphic, electronic, or mechanical, including photocopying, recording, web distribution, taping, or by any information storage retrieval system, without the written permission of the author.

Notice: Examzify makes every reasonable effort to obtain accurate, complete, and timely information about this product from reliable sources.

SAMPLE

Table of Contents

Copyright	1
Table of Contents	2
Introduction	3
How to Use This Guide	4
Questions	5
Answers	8
Explanations	10
Next Steps	15

SAMPLE

Introduction

Preparing for a certification exam can feel overwhelming, but with the right tools, it becomes an opportunity to build confidence, sharpen your skills, and move one step closer to your goals. At Examzify, we believe that effective exam preparation isn't just about memorization, it's about understanding the material, identifying knowledge gaps, and building the test-taking strategies that lead to success.

This guide was designed to help you do exactly that.

Whether you're preparing for a licensing exam, professional certification, or entry-level qualification, this book offers structured practice to reinforce key concepts. You'll find a wide range of multiple-choice questions, each followed by clear explanations to help you understand not just the right answer, but why it's correct.

The content in this guide is based on real-world exam objectives and aligned with the types of questions and topics commonly found on official tests. It's ideal for learners who want to:

- Practice answering questions under realistic conditions,
- Improve accuracy and speed,
- Review explanations to strengthen weak areas, and
- Approach the exam with greater confidence.

We recommend using this book not as a stand-alone study tool, but alongside other resources like flashcards, textbooks, or hands-on training. For best results, we recommend working through each question, reflecting on the explanation provided, and revisiting the topics that challenge you most.

Remember: successful test preparation isn't about getting every question right the first time, it's about learning from your mistakes and improving over time. Stay focused, trust the process, and know that every page you turn brings you closer to success.

Let's begin.

How to Use This Guide

This guide is designed to help you study more effectively and approach your exam with confidence. Whether you're reviewing for the first time or doing a final refresh, here's how to get the most out of your Examzify study guide:

1. Start with a Diagnostic Review

Skim through the questions to get a sense of what you know and what you need to focus on. Your goal is to identify knowledge gaps early.

2. Study in Short, Focused Sessions

Break your study time into manageable blocks (e.g. 30 – 45 minutes). Review a handful of questions, reflect on the explanations.

3. Learn from the Explanations

After answering a question, always read the explanation, even if you got it right. It reinforces key points, corrects misunderstandings, and teaches subtle distinctions between similar answers.

4. Track Your Progress

Use bookmarks or notes (if reading digitally) to mark difficult questions. Revisit these regularly and track improvements over time.

5. Simulate the Real Exam

Once you're comfortable, try taking a full set of questions without pausing. Set a timer and simulate test-day conditions to build confidence and time management skills.

6. Repeat and Review

Don't just study once, repetition builds retention. Re-attempt questions after a few days and revisit explanations to reinforce learning. Pair this guide with other Examzify tools like flashcards, and digital practice tests to strengthen your preparation across formats.

There's no single right way to study, but consistent, thoughtful effort always wins. Use this guide flexibly, adapt the tips above to fit your pace and learning style. You've got this!

Questions

SAMPLE

- 1. What determines whether a drug is ionized or un-ionized?**
 - A. The pH of the tissue it's in
 - B. The drug's pKa
 - C. Temperature
 - D. Presence of carrier proteins

- 2. Which statement is true about albumin binding and free drug fraction for acidic drugs?**
 - A. Decreased plasma albumin increases the free fraction of acidic drugs.
 - B. Increased plasma albumin increases the free fraction of acidic drugs.
 - C. Albumin binding does not affect free fraction for acidic drugs.
 - D. Albumin binding only affects basic drugs.

- 3. What can cause decreased distribution of a drug to tissue?**
 - A. Binding to plasma proteins
 - B. High blood flow to tissues
 - C. Low molecular weight
 - D. High lipid solubility

- 4. What is the value of oral bioavailability F when the reference administration is intravenous?**
 - A. F is 1 by definition.
 - B. F equals AUC_{po} / AUC_{iv} .
 - C. F equals $Dose_{iv} / Dose_{po}$.
 - D. F equals AUC_{iv} / AUC_{po} .

- 5. Which of the following is a typical example of a transdermal agent?**
 - A. Inhaled albuterol
 - B. Oral acetaminophen
 - C. Fentanyl patch
 - D. Intravenous morphine

- 6. What is the preferred route of administration for protein based drugs?**
- A. Intravenous
 - B. Subcutaneous
 - C. Intramuscular
 - D. Oral
- 7. What is meant by a drug's volume of distribution (V_d)?**
- A. The physical volume of blood.
 - B. The volume of urine excreted.
 - C. The volume of drug needed for therapeutic effect.
 - D. Volume in which the drug is distributed if concentration is uniform with plasma.
- 8. What is the effect of enzyme inducers or inhibitors on apparent oral bioavailability of drugs with high first-pass metabolism?**
- A. Inducers decrease F and inhibitors increase F
 - B. Inducers increase F and inhibitors decrease F
 - C. Both inducers and inhibitors increase F
 - D. Both inducers and inhibitors decrease F
- 9. Where might P-glycoproteins be located in the body and why?**
- A. Skeletal muscle tissue
 - B. Brain parenchyma
 - C. Adipose tissue
 - D. Blood-brain barrier, renal tubular cells, intestinal epithelium of lower GI tract
- 10. Active transport in carrier-mediated absorption requires which energy source?**
- A. ATP
 - B. Sunlight
 - C. Adenosine triphosphate (ATP)
 - D. Chemical energy

Answers

SAMPLE

1. A
2. A
3. C
4. A
5. C
6. B
7. D
8. A
9. D
10. C

SAMPLE

Explanations

SAMPLE

1. What determines whether a drug is ionized or un-ionized?

- A. The pH of the tissue it's in
- B. The drug's pKa
- C. Temperature
- D. Presence of carrier proteins

Ionization is driven by the acid-base equilibrium of the drug in its surrounding environment, described by the relation between pH and pKa. The pH of the tissue sets the actual state of ionization in that location: if the local pH favors the non-ionized form for an acidic drug or the non-ionized form for a basic drug, you get more absorption in that site. The pKa of the drug tells you where the equilibrium lies (the pH at which half is ionized), but the immediate determinant you encounter in a given tissue is the tissue's pH itself. Temperature and carrier proteins don't change the ionization state; they affect other properties like rate or distribution but not the charge balance. So, the tissue's pH is the primary factor determining whether the drug is ionized or un-ionized in that environment.

2. Which statement is true about albumin binding and free drug fraction for acidic drugs?

- A. Decreased plasma albumin increases the free fraction of acidic drugs.
- B. Increased plasma albumin increases the free fraction of acidic drugs.
- C. Albumin binding does not affect free fraction for acidic drugs.
- D. Albumin binding only affects basic drugs.

The key idea is that drug activity and clearance depend on how much of the drug is free in the plasma versus bound to proteins. Albumin is the main binding protein for acidic drugs, so most of these drugs are tied up in the bound form and only a small portion is free to act or be cleared. When plasma albumin levels drop, there are fewer binding sites available. That means more of the acidic drug remains unbound, increasing the free fraction. Since only the unbound drug is pharmacologically active and available for distribution and elimination, a decrease in albumin tends to raise the amount of free drug. So, the statement that decreased plasma albumin increases the free fraction of acidic drugs is true. In contrast, increasing albumin would pull more drug into the bound form and lower the free fraction; albumin binding does affect the free fraction for acidic drugs (and is the main determinant here), while basic drugs are more associated with other binding proteins like alpha-1-acid glycoprotein.

3. What can cause decreased distribution of a drug to tissue?

- A. Binding to plasma proteins
- B. High blood flow to tissues
- C. Low molecular weight
- D. High lipid solubility

Distribution to tissues hinges on the free drug fraction; only unbound drug can cross capillary walls and diffuses into tissues. When a drug binds strongly to plasma proteins, the free fraction is small, so less drug is available to leave the bloodstream and enter tissues. This reduces distribution and lowers the apparent volume of distribution. In contrast, high tissue perfusion brings more drug to the area, low molecular weight facilitates diffusion across membranes, and high lipid solubility helps drug penetration into tissues—each of these factors tends to increase distribution. So binding to plasma proteins is the factor that decreases distribution to tissue.

4. What is the value of oral bioavailability F when the reference administration is intravenous?

- A. F is 1 by definition.**
- B. F equals AUC_{po} / AUC_{iv} .
- C. F equals $Dose_{iv} / Dose_{po}$.
- D. F equals AUC_{iv} / AUC_{po} .

The key idea is how bioavailability is scaled to a reference route. When intravenous administration is used as the reference, its bioavailability is defined as 1 (100%) because the drug goes directly into systemic circulation without any absorption barriers. That sets a unity baseline for comparing routes. Therefore, the value of the reference route's bioavailability is 1 by definition, and any discussion of the oral route's bioavailability is about how much of the dose reaches systemic circulation relative to that IV reference. In practice, oral bioavailability is usually less than 1 due to absorption limits and first-pass metabolism, but the IV route itself is defined as 1.

5. Which of the following is a typical example of a transdermal agent?

- A. Inhaled albuterol
- B. Oral acetaminophen
- C. Fentanyl patch**
- D. Intravenous morphine

Transdermal delivery provides systemic drug exposure by releasing medicine through the skin from a patch, giving a steady, long-acting dose without going through the gut or liver first. The fentanyl patch is a classic example because fentanyl is highly lipophilic and can efficiently cross the skin barrier, allowing a gradual amount of drug to enter the bloodstream over days. This route delivers continuous analgesia and avoids first-pass metabolism, which is ideal for chronic pain management. Keep in mind that absorption can be influenced by skin condition and heat, and it's typically used in opioid-tolerant patients due to potency. Inhaled albuterol uses the lungs, oral acetaminophen is absorbed via the gastrointestinal tract, and intravenous morphine is delivered directly into the bloodstream by injection—none of these are transdermal.

6. What is the preferred route of administration for protein based drugs?

- A. Intravenous
- B. Subcutaneous**
- C. Intramuscular
- D. Oral

Protein-based drugs are not suitable for oral use because they're digested by proteolytic enzymes in the gut and don't get reliably into the bloodstream. That's why routes that bypass the digestive system are used. Subcutaneous administration is often preferred because it allows slower, more controlled absorption into the bloodstream, which helps maintain stable levels over time. It also supports convenient, at-home dosing, improving patient adherence for chronic therapy. While intravenous delivery provides immediate and complete bioavailability, it's less practical for routine, long-term treatment and requires clinical settings. Intramuscular injections can be more variable in absorption, and oral dosing is generally ineffective for these drugs. For many protein therapies like insulin and other biologics, subcutaneous dosing offers a good balance of reliable absorption, safety, and patient convenience.

7. What is meant by a drug's volume of distribution (V_d)?

- A. The physical volume of blood.
- B. The volume of urine excreted.
- C. The volume of drug needed for therapeutic effect.
- D. Volume in which the drug is distributed if concentration is uniform with plasma.**

Volume of distribution is the apparent volume into which a drug would need to be distributed to produce the observed plasma concentration if the entire amount in the body were uniformly distributed. It's a theoretical concept, not a physical space. It reflects how widely a drug spreads into body compartments. The concept is captured by the equation $V_d = \text{amount in the body} / \text{plasma drug concentration}$. If the drug mainly stays in the blood, the V_d is small (a few liters). If it distributes into extracellular fluid, V_d is around 12–16 L. If it penetrates tissues and binds there, V_d becomes large (tens of liters or more), indicating extensive tissue distribution. So the right idea is that volume of distribution describes the volume in which the drug would have to be dissolved to match the observed plasma concentration if distribution were uniform.

8. What is the effect of enzyme inducers or inhibitors on apparent oral bioavailability of drugs with high first-pass metabolism?

- A. Inducers decrease F and inhibitors increase F**
- B. Inducers increase F and inhibitors decrease F
- C. Both inducers and inhibitors increase F
- D. Both inducers and inhibitors decrease F

When a drug is heavily affected by first-pass metabolism, its oral bioavailability reflects how much survives gut and liver metabolism before reaching the bloodstream. Enzyme inducers boost the amount of drug-metabolizing enzymes in both the gut wall and liver, speeding up presystemic metabolism and converting more of the dose to inactive forms before it can reach systemic circulation. That lowers the apparent oral bioavailability. Conversely, enzyme inhibitors slow down or block these enzymes, reducing presystemic metabolism and allowing more drug to escape to the circulation, which increases apparent bioavailability. So for drugs with high first-pass metabolism, inducers decrease the apparent oral bioavailability, while inhibitors increase it.

9. Where might P-glycoproteins be located in the body and why?

- A. Skeletal muscle tissue
- B. Brain parenchyma
- C. Adipose tissue
- D. Blood-brain barrier, renal tubular cells, intestinal epithelium of lower GI tract**

P-glycoprotein acts as an efflux transporter that actively pumps many drugs out of cells, shaping how a drug is absorbed, distributed, and eliminated. Its main sites reflect its protective role at interfaces where drugs could accumulate: in the intestinal epithelium, it sits on the apical membrane and pumps substrates back into the gut lumen, reducing oral absorption; in renal tubular cells, it is on the apical (luminal) side and moves drugs into the urine, aiding excretion; in brain capillary endothelial cells forming the blood–brain barrier, it is on the luminal surface facing the blood and pumps substrates back into circulation, limiting drug entry into the brain. This combination explains why P-gp helps protect the CNS, lowers oral bioavailability, and enhances renal clearance. Skeletal muscle and adipose tissue are not the primary functional sites for P-gp's protective transport, and the brain barrier concept specifically points to the blood–brain barrier rather than brain parenchyma itself.

10. Active transport in carrier-mediated absorption requires which energy source?

- A. ATP
- B. Sunlight
- C. Adenosine triphosphate (ATP)
- D. Chemical energy

Active transport moves substances against their concentration gradient, which requires energy. In carrier-mediated absorption, the energy comes from the hydrolysis of ATP. The high-energy phosphate bonds in ATP release energy when ATP is converted to ADP and inorganic phosphate, causing the transporter protein to change shape and actively move the solute uphill. Sunlight isn't used in human carrier-mediated absorption, and while chemical energy is a broad term, the direct and specific energy source here is ATP (adenosine triphosphate).

SAMPLE

Next Steps

Congratulations on reaching the final section of this guide. You've taken a meaningful step toward passing your certification exam and advancing your career.

As you continue preparing, remember that consistent practice, review, and self-reflection are key to success. Make time to revisit difficult topics, simulate exam conditions, and track your progress along the way.

If you need help, have suggestions, or want to share feedback, we'd love to hear from you. Reach out to our team at hello@examzify.com.

Or visit your dedicated course page for more study tools and resources:

<https://drugabsorptiondistib.examzify.com>

We wish you the very best on your exam journey. You've got this!

SAMPLE